Generation Bio

Generation Bio Co. is a genetic medicine company focused on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Generation Bio (GBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Generation Bio (GBIO)

Generation Bio is a stock to monitor for its potential to disrupt the viral gene therapy market. The company is centered around a technology platform that creates non-viral gene therapies that are re-dosable and have the COGs of a biologic.

Generation Bio: Pioneering A New Class Of Gene Therapy

Abercrombie & Fitch

Mattel

Western Digital

Allakos Inc

Emergent BioSolutions

Evolus

Schnitzer Steel Industries Inc

Thomson Reuters

With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.

Abercrombie, Mattel, Western Digital and More Wednesday Afternoon Analyst Calls

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021.

Generation Bio Appoints Ron Cooper to Its Board of Directors

Conagra Brands

Aldeyra Therapeutics

DermTech Inc

Fate Therapeutics

Mersana Therapeutics

Old Republic International

REV Group

B. Riley Financial

Sprout Social

York Water

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there has been due to the pandemic resurgence and political issues.

Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its public offering of 9,200,000 shares of its common stock at a public offering price of $24.50 per share, including 1,200,000 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Generation Bio.

Generation Bio Announces Closing of Public Offering

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a public offering of 8,000,000 shares of its common stock at a public offering price of $24.50 per share. In addition, Generation Bio has granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of common stock at the public offering price, less the underwriting discount and commissions. All of the shares are being offered by Generation Bio.

Generation Bio Announces Pricing of Public Offering

Generation Bio (GBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Generation Bio (GBIO) Catches Eye: Stock Jumps 6.1%

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that the company will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021.

Generation Bio to Present at 39th Annual J.P. Morgan Healthcare Conference

Data confirm delivery of closed-ended DNA to the liver via novel, cell-targeted lipid nanoparticles

Generation Bio Announces Two Non-Viral Gene Therapy Milestone Achievements: Target Levels of Factor VIII Expression in Hemophilia A Mice and Translation of Expression from Mice to Non-Human Primates

Airbnb

The AZEK Company

DoorDash

Vaxcyte

Avidity Biosciences

Vroom

The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.

U.S. IPO Week Ahead: DoorDash And Airbnb Kick Off The Unicorn Parade In A 6 IPO Week

On Track to Advance Lead Programs into Pre-Clinical Development in 2021 Supported by Key Leadership Team Appointments On Track to Advance Lead Programs into Pre-Clinical Development in 2021 Supported by Key Leadership Team Appointments

Generation Bio Reports Third Quarter 2020 Business Updates and Financial Results

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Phillip Samayoa, vice president of strategy and portfolio development, will present a company overview at the annual Cell & Gene Meeting on the Mesa. The presentation will be available for registered participants to view on demand throughout the conference, to be held virtually Oct. 12-16, at meetingonthemesa.com.

Generation Bio to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass., Sept.  24, 2020  (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies 2020 Virtual Gene Therapy/Editing Summit on Thursday, Oct. 1 at 11:00 a.m. ET.

Generation Bio to Present at the Jefferies 2020 Virtual Gene Therapy/Editing Summit

CAMBRIDGE, Mass., Aug.  11, 2020  (GLOBE NEWSWIRE) --  Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today reported recent business highlights and second quarter financial results.

Generation Bio Reports Business Updates and Second Quarter 2020 Financial Results

CAMBRIDGE, Mass., Aug.  05, 2020  (GLOBE NEWSWIRE) --  Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that management will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, Aug. 12, 2020 at 10:20 a.m. ET.

Generation Bio to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., July  22, 2020  (GLOBE NEWSWIRE) --  Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that Matthew Norkunas, M.D., MBA, has been appointed chief financial officer.

Generation Bio Appoints Matthew Norkunas, M.D., MBA as Chief Financial Officer

CAMBRIDGE, Mass., June  16, 2020  (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its initial public offering of 12,105,263 shares of its common stock at an initial public offering price of $19.00 per share, including 1,578,947 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Generation Bio.

Generation Bio Announces Closing of Initial Public Offering

Shares of Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, soared 23% Friday in their trading debut, after the IPO was upsized and priced at $19 a share, the high end of its price range.

Generation Bio shares soar 23% in trading debut

Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, priced its upsized initial public offering at $19 a share, the high end of its price range.

Generation Bio prices upsized IPO at $19 a share to raise $199.5 million

CAMBRIDGE, Mass., June  11, 2020  (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of its initial public offering of 10,526,316 shares of its common stock at an initial public offering price of $19.00 per share. In addition, Generation Bio has granted the underwriters a 30-day option to purchase up to 1,578,947 additional shares of common stock at the initial public offering price, less the underwriting discount and commissions. All of the shares are being offered by Generation Bio.

Generation Bio Announces Pricing of Initial Public Offering

News for Generation Bio Stock (GBIO)